- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06016127
Cryoneurolysis for Facet Mediated Chronic Low Back Pain
A Single-center, Randomized, Pilot Study to Assess Iovera° Lumbar Medial Branch Cryoneurolysis vs Lumbar Radiofrequency Ablation for Facet Mediated Chronic Low Back Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-center, randomized, pilot study in adult subjects with facet mediated CLBP. Thirty (30) subjects are planned for initial enrollment and will be randomized 1:1 to receive ioveraº medial branch cryoneurolysis or radiofrequency ablation.
This study is designed to determine if a full efficacy RCT can be successfully conducted using the procedures and protocols described in the current pilot study protocol, or if protocol modifications are necessary before moving forward with a full efficacy RCT. Furthermore, the study will assess the feasibility of the outcome measurements employed, construct a foundation for sample size calculation, and the acceptability/practicality of conducting the full efficacy RCT.
Randomization to treatment groups according to the randomization assignment will be performed on the day of treatment. The treatment groups are:
- Group 1: subjects will receive iovera° cryoneurolysis to the medial branch nerves of the lumbar spine
- Group 2: subjects will receive RFA to the medial branch nerves of the lumbar spine
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Saratoga Springs, New York, United States, 12866
- The Albany & Saratoga Centers For Pain Management
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female volunteers, at least 18 years of age at screening
- Primary complaint of axial low-back pain suggestive of unilateral or bilateral facet joint involvement (i.e., facet mediated CLBP)
- Low back pain is chronic (i.e., > 3 months' duration)
- Low back pain score of ≥ 4 (i.e., moderate pain) on the 0 to 10 NRS or functional impairment at screening
- Successful trial of two diagnostic medial branch blocks consisting of two positive blocks with local anesthetic only (i.e., no steroids) that results in at least 50% relief of primary (index) pain for the duration of the local anesthetic used or history of a positive response to prior radiofrequency treatment (i.e., ≥ 6 months prior to enrollment)
- Failure of at least three months of conservative non-operative therapy (e.g., physical therapy, chiropractic care, spinal injections, NSAIDs or other appropriate analgesics),
- Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments
Exclusion Criteria:
- Active workers' compensation, personal injury, Social Security disability insurance (SSDI), or other litigation/compensation related to the spine
Serious spinal disorders (verified on magnetic resonance imaging (MRI)) that may impact outcomes, including any of the following:
- Suspected cauda equina syndrome (e.g., bowel/bladder dysfunction)
- Infection
- Tumor
- Traumatic fracture
- Systemic inflammatory spondyloarthropathy
- Lumbar radiculopathy/radiculitis (i.e., root irritation and deficit)
- Neurogenic claudication
- Prior lumbar spinal fusion surgery
- Comorbidity that, in the judgment of the Investigator, may affect the subject's ability to participate in the study including lumbar radiculopathy and neuropathic pain disorder
- Currently pregnant, nursing, or planning to become pregnant during the study
Known contraindication to study devices, including any of the following:
- Cryoglobulinemia
- Paroxysmal cold hemoglobinuria
- Cold urticaria
- Raynaud's disease
- Open and/or infected wounds at or near the treatment site
- Coagulopathy
- 3.5-inch needle cannot be used in the low back region because of habitus
- Severe chronic pain disorder that in the opinion of the investigator may impact postsurgical outcomes
Presence of any of the following:
- Spinal neurostimulator
- Intrathecal analgesic drug pump
Current manifestation of poorly controlled mental illness that in the opinion of the investigator may meaningfully impact treatment outcomes, including any of the following:
- Mood disorder (e.g., major depression, bipolar)
- Psychotic disorder (e.g., schizophrenia)
- Subject received other spine intervention/therapies in the 30 days prior to block administration (e.g., spinal injections, minimally invasive therapies, surgical therapies)
- Subject received radiofrequency ablation in the low back region ≤ 6 months before study enrollment
History, suspicion, or clinical manifestation of:
- Alcohol abuse or dependence
- Illicit drug use
- Opioid abuse or dependence (≥40 mg MED PO/day in past 30 days) Given the COVID-19 pandemic, the subject must be medically fit/cleared for treatment by the investigator. If there is a concern about a subject's recent or potential exposure to COVID-19, or if the subject is not medically fit/cleared for treatment due to suspected COVID-19 illness/symptoms (or other serious illness), the subject must be excluded per Exclusion criterion #4.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cryoneurolysis
Subjects will receive iovera° cryoneurolysis to the medial branch nerves of the lumbar spine
|
The iovera° system consists of a reusable, portable Handpiece, along with single patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges.
The iovera° system produces the desired effect through initiation of a cooling cycle.
Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow.
The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen.
The "190" Smart Tip will be used in this study.
Other Names:
|
Active Comparator: Radiofrequency ablation
Subjects will receive RFA to the medial branch nerves of the lumbar spine
|
The RFA system consists of a Cosman, G4 Generator.
The needles used are 20-gauge, 10cm long with a 10mm active tip manufactured by Cosman.
A grounding pad, also manufactured by Cosman, is placed on the upper thigh for each procedure and connected to the G4 Generator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of cryoneurolysis as compared to radiofrequency ablation (RFA)
Time Frame: 0-12 months
|
Safety will be assessed as the number of subjects with reported treatment-related adverse related to cryoneurolysis or RFA.
|
0-12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain intensity as measured by 11-point Numeric Rating Scale (NRs)
Time Frame: 0-12 months
|
Subjects will evaluate their pain in the low back region using an 11-point Numeric Rating Scale (NRS), where 0=no pain and 10=worst possible pain. Subjects will evaluate how much pain they are currently experiencing and their worst and average level of pain over the past 24 hours. |
0-12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in functional disability
Time Frame: 0-12 months
|
Function disability will be measured by the Oswestry Disability Index.
The score ranges from 0-50, with lower scores reflecting milder disability.
|
0-12 months
|
Change in Patients' Global Impression of Change
Time Frame: 0-12 months
|
The Patients' Global Impression of Change (PGIC) is a 7-point patient self-reporting scale of overall change in activity limitations, symptoms, emotions, and quality of life ranging from 1) no change 2) hardly any change 3) no noticeable change 4) change has not made any real difference 5) a slight but noticeable change 6) a definite improvement 7) considerable improvement. The scale also assesses degree of change since beginning care (0=much better, 10=much worse). |
0-12 months
|
Satisfaction with pain management
Time Frame: 0-12 months
|
Subject satisfaction with pain management as measured on a scale ranging from 1) extremely dissatisfied 2) dissatisfied 3) neither satisfied nor dissatisfied 4) satisfied 5) extremely satisfied.
|
0-12 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRS-107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
University School of Physical Education in WroclawCompletedLow Back Pain | Low Back Pain, Mechanical | Low Back Pain, PosturalPoland
-
Texas Woman's UniversityTexas Physical Therapy AssociationCompletedLow Back Pain | Chronic Low Back Pain | Subacute Low Back PainUnited States
-
University of ParmaKing's College London; Helmholtz Zentrum München; GENOS; Ip Research Consulting... and other collaboratorsUnknownChronic Low Back Pain | Acute Low Back PainUnited States, Australia, Belgium, Croatia, Italy, United Kingdom
-
Ache Laboratorios Farmaceuticos S.A.Unknown
-
Palmer College of ChiropracticDepartment of Health and Human ServicesCompletedChronic Low Back Pain | Subacute Low Back PainUnited States
-
Universität Duisburg-EssenSiemens-BetriebskrankenkasseCompletedChronic Low Back Pain | Recurrent Low Back Pain
-
Karolinska InstitutetCompletedChronic Low Back Pain | Recurrent Low Back Pain | Persistent Low Back PainSweden
-
Apsen Farmaceutica S.A.CompletedLow Back Pain | Low Back Pain, Mechanical | Acute Low Back PainBrazil
Clinical Trials on iovera system
-
Pacira Pharmaceuticals, IncRecruitingSpasticity, Cerebral or Spinal ConditionUnited States
-
Northern California Research Trials, Inc.Pacira Pharmaceuticals, Inc; NorthBay HealthcareActive, not recruitingPain Management | Morton's NeuromaUnited States
-
Pacira Pharmaceuticals, IncCompletedArthritis of the KneeUnited States
-
Pacira CryoTech, Inc., a wholly owned subsidiary...CompletedTotal Knee ArthroplastyUnited States
-
University of Kansas Medical CenterActive, not recruitingAnkle OsteoarthritisUnited States
-
Pacira CryoTech, Inc., a wholly owned subsidiary...WithdrawnAnterior Cruciate Ligament ReconstructionUnited States
-
Pacira CryoTech, Inc., a wholly owned subsidiary...CompletedForehead WrinklesUnited States
-
Pacira CryoTech, Inc., a wholly owned subsidiary...Completed
-
Fondren Orthopedic Group L.L.P.Withdrawn
-
Pacira CryoTech, Inc., a wholly owned subsidiary...Withdrawn